Appendix B: Sources of Evidence
i) The following documentation and opinion was made available to the Committee:
a) Assessment Report The effectiveness of inhaler devices for young children with asthma; Prepared by Payne N & Beard S, Trent Institute for Health Services Research, School of Health & Related Research, University of Sheffield;Wright, Brocklebank,D & Ram F, Bradford Hospitals NHS Trust; Taylor RS, National Institute for Clinical Excellence. March 2000.
b) Manufacturer/Sponsor submissions:
ii. Boehringer Inglheim Ltd.
iii. Aventis Pharma (formerly Rhône-Poulenc Rorer)
iv. Boehringer Inglheim Ltd.
v. Glaxo Wellcome
vi. 3M Health Care Ltd.
vii. Norton Healthcare
viii.Yamanouchi Pharma Ltd.
c) Professional/specialist group, patient/carer group and trade association submissions;
i. Association of British Health-Care Industries
ii. British Medical Association
iii. British Thoracic Society
iv. National Asthma Campaign
v. Royal College of Nursing
vi. Royal College of Paediatrics & Child Health
vii. Royal College of Physicians
ii) The following experts were invited to make submissions to the Committee:
a) Dr Andrew Bush, Reader in Paediatric Respirology & Honorary Consultant Paediatric Chest Physician, Royal Brompton Hospital, London.
b) Dr C O'Callaghan, Senior Lecturer & Consultant Paediatrician,University of Leicester & Leicester Royal Infirmary Children's Hospital.